NEW YORK (TheStreet) -- Pfizer
(PFE) stock is slipping on Monday after the company posted first-quarter profits 15% lower than a year earlier and revenue down 9%.
By midmorning, shares had dropped 2.1% to $30.11.
The pharmaceuticals company reported net income of $2.3 billion over the three months to March. Excluding one-time items, net income of 57 cents a share beat expectations by 2 cents, according to analysts polled by Thomson Reuters.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Revenue of $11.3 billion fell short of analysts' estimates of $12.1 billion.
The weaker-than-expected report comes days after its latest offer to purchase British drugmaker AstraZeneca for $106 billion was rejected.
Pfizer has recently suffered lower revenues and earnings as key patents expire, giving way to the development of cheaper generic brands. This has been especially true for Pfizer's cholesterol drug Lipitor, the patent for which expired in 2011.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
WATCH: More market update videos on TheStreet TV
| More videos from Keris Alison Lahiff
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts